1. Executive summary |
2. Global Therapeutic Drug Monitoring (TDM) Market Introduction |
2.1. Global Therapeutic Drug Monitoring (TDM) Market – Taxonomy |
2.2. Global Therapeutic Drug Monitoring (TDM) Market –Definitions |
2.2.1. By Drug Type |
2.2.2. By Technology |
2.2.3. By End User |
2.2.4. By Region |
3. Global Therapeutic Drug Monitoring (TDM) Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Reimbursement Scenario for Top 5 Countries |
3.6. Global Therapeutic Drug Monitoring (TDM) Market Dynamics – Factors Impact Analysis |
4. Global Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 |
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Millions and Volume in Millions) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Therapeutic Drug Monitoring (TDM) Market, By Drug Type, 2017 – 2021 and Forecast, 2018 – 2028 |
5.1. Antibiotics |
5.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.1.3.1. Chloramphenicol |
5.1.3.2. Linezolid |
5.1.3.3. Piperacillin |
5.1.3.4. Rifampicin |
5.1.3.5. Tazobactam |
5.1.3.6. Vancomycin |
5.1.3.7. Gentamicin |
5.1.3.8. Amikacin |
5.1.3.9. Tobramycin |
5.1.3.10. Teicoplanin |
5.1.3.11. Ceftazidime |
5.1.3.12. Meropenem |
5.1.3.13. Nafcillin |
5.1.3.14. Ticarcillin |
5.2. Addiction Therapeutics |
5.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.2.3.1. Buprenorphine |
5.2.3.2. Methadone |
5.2.3.3. Naltrexone |
5.2.3.4. Propoxyphene |
5.2.3.5. Tapentadol |
5.3. Alzheimer Disease |
5.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.3.3.1. Donezepil |
5.3.3.2. Galantamine |
5.3.3.3. Memantine |
5.4. Analeptics |
5.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.4.3.1. Caffeine |
5.4.3.2. Theophylline |
5.5. Analgesics |
5.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.5.3.1. Acetaminophen |
5.5.3.2. Ibuprofen |
5.5.3.3. Naproxen |
5.5.3.4. Salicylate |
5.5.3.5. Tramadol |
5.6. Antiarrhythmic |
5.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.6.3.1. Amiodarone |
5.6.3.2. Digoxin |
5.6.3.3. Flecainide |
5.6.3.4. Mexiletine |
5.6.3.5. Verapamil |
5.6.3.6. N-acetylprocainamide, NAPA |
5.6.3.7. Digitoxin |
5.6.3.8. Lidocaine |
5.6.3.9. Procainimide |
5.6.3.10. Quinidine |
5.7. Anticancer |
5.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.7.3.1. 5-Fluorouracil |
5.7.3.2. Docetaxel |
5.7.3.3. Methotrexate |
5.7.3.4. Mylmatinib |
5.7.3.5. Paclitaxel |
5.7.3.6. Imatinib |
5.7.3.7. Busulfan |
5.8. Anticoagulants |
5.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
5.8.3.1. Dabigatran |
5.8.3.2. Warfarin |
5.9. Antidepressants |
5.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.9.3. Market Opportunity Analysis |
5.9.3.1. Citalopram |
5.9.3.2. Fluoxetine |
5.9.3.3. Fluvoxamine |
5.9.3.4. Sertraline |
5.9.3.5. Venlafaxine |
5.9.3.6. Desmethylfluoxetine |
5.9.3.7. Trazodone |
5.9.3.8. Protriptyline |
5.9.3.9. Nortriptyline |
5.9.3.10. Imipramine |
5.9.3.11. Desipramine |
5.9.3.12. Doxepin |
5.9.3.13. Clomipramine |
5.9.3.14. Bupropion |
5.9.3.15. Amitriptyline |
5.9.3.16. Nortriptyline |
5.10. Antiepileptics |
5.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.10.3. Market Opportunity Analysis |
5.10.3.1. Ethosuximide |
5.10.3.2. Felbamate |
5.10.3.3. Gabapentin |
5.10.3.4. Lamotrigine |
5.10.3.5. Pregabaline |
5.10.3.6. Topiramate |
5.10.3.7. Zonisamide |
5.10.3.8. Carbamazepine |
5.10.3.9. Valproic Acid |
5.10.3.10. Lacosamide |
5.10.3.11. Levetiracetam |
5.10.3.12. Phenobarbital |
5.10.3.13. Phenytoin |
5.10.3.14. Rufinamide |
5.10.3.15. Tiagabine |
5.10.3.16. Vigabatrin |
5.10.3.17. Primidone |
5.11. Anti-HIV |
5.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.11.3. Market Opportunity Analysis |
5.11.3.1. Atazanavir |
5.11.3.2. Indinavir |
5.11.3.3. Lopinavir |
5.11.3.4. Nelfinavir |
5.11.3.5. Ritonavir |
5.11.3.6. Saquinavir |
5.11.3.7. Darunavir |
5.11.3.8. Fosamprenavir |
5.11.3.9. Tipranavir |
5.11.3.10. Efavirenz |
5.11.3.11. Etravirine |
5.11.3.12. Nevirapine |
5.11.3.13. Rilpivirine |
5.12. Antihypertensive |
5.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.12.3. Market Opportunity Analysis |
5.12.3.1. Propronolol |
5.13. Antipsychotics |
5.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.13.3. Market Opportunity Analysis |
5.13.3.1. Aripiprazole |
5.13.3.2. Clozapine |
5.13.3.3. Haloperidol |
5.13.3.4. Olanzapine |
5.13.3.5. Ziprasidone |
5.13.3.6. Chlorpromazine |
5.13.3.7. Lithium |
5.13.3.8. Lurasidone |
5.13.3.9. Paliperidone |
5.13.3.10. Perphenazine |
5.13.3.11. Quetiapine |
5.13.3.12. Risperidone |
5.13.3.13. Thiothixene |
5.14. Hormones |
5.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.14.3. Market Opportunity Analysis |
5.14.3.1. T3 |
5.14.3.2. T4 |
5.14.3.3. Corticosteroids |
5.14.3.4. TSH |
5.15. Immuno-Suppressants |
5.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.15.3. Market Opportunity Analysis |
5.15.3.1. Cyclosporin A |
5.15.3.2. Everolimus |
5.15.3.3. Mycophenolic acid |
5.15.3.4. Sirolimus |
5.15.3.5. Tacrolimus |
5.16. Antifungals |
5.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
5.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.16.3. Market Opportunity Analysis |
5.16.3.1. Fluconazole |
5.16.3.2. Itraconazole |
5.16.3.3. Voriconazole |
5.16.3.4. Posoconazole |
6. Global Therapeutic Drug Monitoring (TDM) Market Forecast, By Technology Type, 2017 – 2021 and Forecast, 2022 – 2028 |
6.1. Immuno- Assay |
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions)) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Mass Spectrometry |
6.2.1. LC-MS/MS |
6.2.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions)) |
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.1.3. Market Opportunity Analysis |
6.3. GC-MS/MS |
6.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions)) |
6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.1.3. Market Opportunity Analysis |
6.4. Others (Electrophoresis, Proteomics, etc.) |
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume, Millions)) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Therapeutic Drug Monitoring (TDM) Market Forecast, By End-User Type, 2017 – 2021 and Forecast, 2022 – 2028 |
7.1. Hospital Laboratories |
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Private Laboratories |
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Therapeutic Drug Monitoring (TDM) Market Analysis, By Region, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume Millions)) |
8.1. North America |
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions)) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe, Middle East & Africa |
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions)) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Latin America |
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions)) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Asia Pacific |
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2018 – 2024 ((Revenue, USD Millions) (Volume, Millions)) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Global Therapeutic Drug Monitoring (TDM) Market – Opportunity Analysis Index, By Drug Type, By Technology, and Region, 2018 – 2024 |
9. North America Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028 |
9.1. Antibiotics |
9.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.1.3.1. Chloramphenicol |
9.1.3.2. Linezolid |
9.1.3.3. Piperacillin |
9.1.3.4. Rifampicin |
9.1.3.5. Tazobactam |
9.1.3.6. Vancomycin |
9.1.3.7. Gentamicin |
9.1.3.8. Amikacin |
9.1.3.9. Tobramycin |
9.1.3.10. Teicoplanin |
9.1.3.11. Ceftazidime |
9.1.3.12. Meropenem |
9.1.3.13. Nafcillin |
9.1.3.14. Ticarcillin |
9.2. Addiction Therapeutics |
9.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.2.3.1. Buprenorphine |
9.2.3.2. Methadone |
9.2.3.3. Naltrexone |
9.2.3.4. Propoxyphene |
9.2.3.5. Tapentadol |
9.3. Alzheimer Disease |
9.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.3.3.1. Donezepil |
9.3.3.2. Galantamine |
9.3.3.3. Memantine |
9.4. Analeptics |
9.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.4.3.1. Caffeine |
9.4.3.2. Theophylline |
9.5. Analgesics |
9.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.5.3.1. Acetaminophen |
9.5.3.2. Ibuprofen |
9.5.3.3. Naproxen |
9.5.3.4. Salicylate |
9.5.3.5. Tramadol |
9.6. Antiarrhythmic |
9.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.6.3. Market Opportunity Analysis |
9.6.3.1. Amiodarone |
9.6.3.2. Digoxin |
9.6.3.3. Flecainide |
9.6.3.4. Mexiletine |
9.6.3.5. Verapamil |
9.6.3.6. N-acetylprocainamide, NAPA |
9.6.3.7. Digitoxin |
9.6.3.8. Lidocaine |
9.6.3.9. Procainimide |
9.6.3.10. Quinidine |
9.7. Anticancer |
9.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.7.3. Market Opportunity Analysis |
9.7.3.1. 5-Fluorouracil |
9.7.3.2. Docetaxel |
9.7.3.3. Methotrexate |
9.7.3.4. Mylmatinib |
9.7.3.5. Paclitaxel |
9.7.3.6. Imatinib |
9.7.3.7. Busulfan |
9.8. Anticoagulants |
9.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.8.3. Market Opportunity Analysis |
9.8.3.1. Dabigatran |
9.8.3.2. Warfarin |
9.9. Antidepressants |
9.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.9.3. Market Opportunity Analysis |
9.9.3.1. Citalopram |
9.9.3.2. Fluoxetine |
9.9.3.3. Fluvoxamine |
9.9.3.4. Sertraline |
9.9.3.5. Venlafaxine |
9.9.3.6. Desmethylfluoxetine |
9.9.3.7. Trazodone |
9.9.3.8. Protriptyline |
9.9.3.9. Nortriptyline |
9.9.3.10. Imipramine |
9.9.3.11. Desipramine |
9.9.3.12. Doxepin |
9.9.3.13. Clomipramine |
9.9.3.14. Bupropion |
9.9.3.15. Amitriptyline |
9.9.3.16. Nortriptyline |
9.10. Antiepileptics |
9.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.10.3. Market Opportunity Analysis |
9.10.3.1. Ethosuximide |
9.10.3.2. Felbamate |
9.10.3.3. Gabapentin |
9.10.3.4. Lamotrigine |
9.10.3.5. Pregabaline |
9.10.3.6. Topiramate |
9.10.3.7. Zonisamide |
9.10.3.8. Carbamazepine |
9.10.3.9. Valproic Acid |
9.10.3.10. Lacosamide |
9.10.3.11. Levetiracetam |
9.10.3.12. Phenobarbital |
9.10.3.13. Phenytoin |
9.10.3.14. Rufinamide |
9.10.3.15. Tiagabine |
9.10.3.16. Vigabatrin |
9.10.3.17. Primidone |
9.11. Anti-HIV |
9.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.11.3. Market Opportunity Analysis |
9.11.3.1. Atazanavir |
9.11.3.2. Indinavir |
9.11.3.3. Lopinavir |
9.11.3.4. Nelfinavir |
9.11.3.5. Ritonavir |
9.11.3.6. Saquinavir |
9.11.3.7. Darunavir |
9.11.3.8. Fosamprenavir |
9.11.3.9. Tipranavir |
9.11.3.10. Efavirenz |
9.11.3.11. Etravirine |
9.11.3.12. Nevirapine |
9.11.3.13. Rilpivirine |
9.12. Antihypertensive |
9.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.12.3. Market Opportunity Analysis |
9.12.3.1. Propronolol |
9.13. Antipsychotics |
9.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.13.3. Market Opportunity Analysis |
9.13.3.1. Aripiprazole |
9.13.3.2. Clozapine |
9.13.3.3. Haloperidol |
9.13.3.4. Olanzapine |
9.13.3.5. Ziprasidone |
9.13.3.6. Chlorpromazine |
9.13.3.7. Lithium |
9.13.3.8. Lurasidone |
9.13.3.9. Paliperidone |
9.13.3.10. Perphenazine |
9.13.3.11. Quetiapine |
9.13.3.12. Risperidone |
9.13.3.13. Thiothixene |
9.14. Hormones |
9.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.14.3. Market Opportunity Analysis |
9.14.3.1. T3 |
9.14.3.2. T4 |
9.14.3.3. Corticosteroids |
9.14.3.4. TSH |
9.15. Immuno-Suppressants |
9.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.15.3. Market Opportunity Analysis |
9.15.3.1. Cyclosporin A |
9.15.3.2. Everolimus |
9.15.3.3. Mycophenolic acid |
9.15.3.4. Sirolimus |
9.15.3.5. Tacrolimus |
9.16. Antifungals |
9.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
9.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.16.3. Market Opportunity Analysis |
9.16.3.1. Fluconazole |
9.16.3.2. Itraconazole |
9.16.3.3. Voriconazole |
9.16.3.4. Posoconazole |
9.17. Immuno- Assay |
9.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.17.3. Market Opportunity Analysis |
9.18. Mass Spectrometry |
9.18.1. LC-MS/MS |
9.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.18.1.3. Market Opportunity Analysis |
9.18.2. GC-MS/MS |
9.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.18.2.3. Market Opportunity Analysis |
9.19. Others (Electrophoresis, Proteomics, etc.) |
9.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.19.3. Market Opportunity Analysis |
9.20. North America Therapeutic Drug Monitoring (TDM) Market By End User |
9.20.1. Hospital Laboratories |
9.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.20.1.3. Market Opportunity Analysis |
9.20.2. Private Laboratories |
9.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.20.2.3. Market Opportunity Analysis |
9.21. North America Therapeutic Drug Monitoring (TDM) Market By Country |
9.21.1. United States |
9.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.21.1.3. Market Opportunity Analysis |
9.21.2. Canada |
9.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
9.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.21.2.3. Market Opportunity Analysis |
9.22. North America Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends |
10. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028 |
10.1. Antibiotics |
10.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.1.3. Market Opportunity Analysis |
10.1.3.1. Chloramphenicol |
10.1.3.2. Linezolid |
10.1.3.3. Piperacillin |
10.1.3.4. Rifampicin |
10.1.3.5. Tazobactam |
10.1.3.6. Vancomycin |
10.1.3.7. Gentamicin |
10.1.3.8. Amikacin |
10.1.3.9. Tobramycin |
10.1.3.10. Teicoplanin |
10.1.3.11. Ceftazidime |
10.1.3.12. Meropenem |
10.1.3.13. Nafcillin |
10.1.3.14. Ticarcillin |
10.2. Addiction Therapeutics |
10.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.2.3. Market Opportunity Analysis |
10.2.3.1. Buprenorphine |
10.2.3.2. Methadone |
10.2.3.3. Naltrexone |
10.2.3.4. Propoxyphene |
10.2.3.5. Tapentadol |
10.3. Alzheimer Disease |
10.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.3.3. Market Opportunity Analysis |
10.3.3.1. Donezepil |
10.3.3.2. Galantamine |
10.3.3.3. Memantine |
10.4. Analeptics |
10.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.4.3. Market Opportunity Analysis |
10.4.3.1. Caffeine |
10.4.3.2. Theophylline |
10.5. Analgesics |
10.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.5.3. Market Opportunity Analysis |
10.5.3.1. Acetaminophen |
10.5.3.2. Ibuprofen |
10.5.3.3. Naproxen |
10.5.3.4. Salicylate |
10.5.3.5. Tramadol |
10.6. Antiarrhythmic |
10.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.6.3. Market Opportunity Analysis |
10.6.3.1. Amiodarone |
10.6.3.2. Digoxin |
10.6.3.3. Flecainide |
10.6.3.4. Mexiletine |
10.6.3.5. Verapamil |
10.6.3.6. N-acetylprocainamide, NAPA |
10.6.3.7. Digitoxin |
10.6.3.8. Lidocaine |
10.6.3.9. Procainimide |
10.6.3.10. Quinidine |
10.7. Anticancer |
10.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.7.3. Market Opportunity Analysis |
10.7.3.1. 5-Fluorouracil |
10.7.3.2. Docetaxel |
10.7.3.3. Methotrexate |
10.7.3.4. Mylmatinib |
10.7.3.5. Paclitaxel |
10.7.3.6. Imatinib |
10.7.3.7. Busulfan |
10.8. Anticoagulants |
10.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.8.3. Market Opportunity Analysis |
10.8.3.1. Dabigatran |
10.8.3.2. Warfarin |
10.9. Antidepressants |
10.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.9.3. Market Opportunity Analysis |
10.9.3.1. Citalopram |
10.9.3.2. Fluoxetine |
10.9.3.3. Fluvoxamine |
10.9.3.4. Sertraline |
10.9.3.5. Venlafaxine |
10.9.3.6. Desmethylfluoxetine |
10.9.3.7. Trazodone |
10.9.3.8. Protriptyline |
10.9.3.9. Nortriptyline |
10.9.3.10. Imipramine |
10.9.3.11. Desipramine |
10.9.3.12. Doxepin |
10.9.3.13. Clomipramine |
10.9.3.14. Bupropion |
10.9.3.15. Amitriptyline |
10.9.3.16. Nortriptyline |
10.10. Antiepileptics |
10.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.10.3. Market Opportunity Analysis |
10.10.3.1. Ethosuximide |
10.10.3.2. Felbamate |
10.10.3.3. Gabapentin |
10.10.3.4. Lamotrigine |
10.10.3.5. Pregabaline |
10.10.3.6. Topiramate |
10.10.3.7. Zonisamide |
10.10.3.8. Carbamazepine |
10.10.3.9. Valproic Acid |
10.10.3.10. Lacosamide |
10.10.3.11. Levetiracetam |
10.10.3.12. Phenobarbital |
10.10.3.13. Phenytoin |
10.10.3.14. Rufinamide |
10.10.3.15. Tiagabine |
10.10.3.16. Vigabatrin |
10.10.3.17. Primidone |
10.11. Anti-HIV |
10.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.11.3. Market Opportunity Analysis |
10.11.3.1. Atazanavir |
10.11.3.2. Indinavir |
10.11.3.3. Lopinavir |
10.11.3.4. Nelfinavir |
10.11.3.5. Ritonavir |
10.11.3.6. Saquinavir |
10.11.3.7. Darunavir |
10.11.3.8. Fosamprenavir |
10.11.3.9. Tipranavir |
10.11.3.10. Efavirenz |
10.11.3.11. Etravirine |
10.11.3.12. Nevirapine |
10.11.3.13. Rilpivirine |
10.12. Antihypertensive |
10.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.12.3. Market Opportunity Analysis |
10.12.3.1. Propronolol |
10.13. Antipsychotics |
10.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.13.3. Market Opportunity Analysis |
10.13.3.1. Aripiprazole |
10.13.3.2. Clozapine |
10.13.3.3. Haloperidol |
10.13.3.4. Olanzapine |
10.13.3.5. Ziprasidone |
10.13.3.6. Chlorpromazine |
10.13.3.7. Lithium |
10.13.3.8. Lurasidone |
10.13.3.9. Paliperidone |
10.13.3.10. Perphenazine |
10.13.3.11. Quetiapine |
10.13.3.12. Risperidone |
10.13.3.13. Thiothixene |
10.14. Hormones |
10.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.14.3. Market Opportunity Analysis |
10.14.3.1. T3 |
10.14.3.2. T4 |
10.14.3.3. Corticosteroids |
10.14.3.4. TSH |
10.15. Immuno-Suppressants |
10.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.15.3. Market Opportunity Analysis |
10.15.3.1. Cyclosporin A |
10.15.3.2. Everolimus |
10.15.3.3. Mycophenolic acid |
10.15.3.4. Sirolimus |
10.15.3.5. Tacrolimus |
10.16. Antifungals |
10.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
10.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.16.3. Market Opportunity Analysis |
10.16.3.1. Fluconazole |
10.16.3.2. Itraconazole |
10.16.3.3. Voriconazole |
10.16.3.4. Posoconazole |
10.17. Immuno- Assay |
10.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.17.3. Market Opportunity Analysis |
10.18. Mass Spectrometry |
10.18.1. LC-MS/MS |
10.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.18.1.3. Market Opportunity Analysis |
10.18.2. GC-MS/MS |
10.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.18.2.3. Market Opportunity Analysis |
10.19. Others (Electrophoresis, Proteomics, etc.) |
10.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.19.3. Market Opportunity Analysis |
10.20. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market By End User |
10.20.1. Hospital Laboratories |
10.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.20.1.3. Market Opportunity Analysis |
10.20.2. Private Laboratories |
10.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.20.2.3. Market Opportunity Analysis |
10.21. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market By Country |
10.21.1. U.K. |
10.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.21.1.3. Market Opportunity Analysis |
10.21.2. Germany |
10.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.21.2.3. Market Opportunity Analysis |
10.21.3. France |
10.21.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.21.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.21.3.3. Market Opportunity Analysis |
10.21.4. Italy |
10.21.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.21.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.21.4.3. Market Opportunity Analysis |
10.21.5. Belgium |
10.21.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.21.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.21.5.3. Market Opportunity Analysis |
10.21.6. Spain |
10.21.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.21.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.21.6.3. Market Opportunity Analysis |
10.21.7. Rest of Europe, Middle East and Africa |
10.21.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
10.21.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
10.21.7.3. Market Opportunity Analysis |
10.22. Europe, Middle East & Africa Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends |
11. Latin America Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028 |
11.1. Antibiotics |
11.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.1.3. Market Opportunity Analysis |
11.1.3.1. Chloramphenicol |
11.1.3.2. Linezolid |
11.1.3.3. Piperacillin |
11.1.3.4. Rifampicin |
11.1.3.5. Tazobactam |
11.1.3.6. Vancomycin |
11.1.3.7. Gentamicin |
11.1.3.8. Amikacin |
11.1.3.9. Tobramycin |
11.1.3.10. Teicoplanin |
11.1.3.11. Ceftazidime |
11.1.3.12. Meropenem |
11.1.3.13. Nafcillin |
11.1.3.14. Ticarcillin |
11.2. Addiction Therapeutics |
11.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.2.3. Market Opportunity Analysis |
11.2.3.1. Buprenorphine |
11.2.3.2. Methadone |
11.2.3.3. Naltrexone |
11.2.3.4. Propoxyphene |
11.2.3.5. Tapentadol |
11.3. Alzheimer Disease |
11.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.3.3. Market Opportunity Analysis |
11.3.3.1. Donezepil |
11.3.3.2. Galantamine |
11.3.3.3. Memantine |
11.4. Analeptics |
11.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.4.3. Market Opportunity Analysis |
11.4.3.1. Caffeine |
11.4.3.2. Theophylline |
11.5. Analgesics |
11.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.5.3. Market Opportunity Analysis |
11.5.3.1. Acetaminophen |
11.5.3.2. Ibuprofen |
11.5.3.3. Naproxen |
11.5.3.4. Salicylate |
11.5.3.5. Tramadol |
11.6. Antiarrhythmic |
11.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.6.3. Market Opportunity Analysis |
11.6.3.1. Amiodarone |
11.6.3.2. Digoxin |
11.6.3.3. Flecainide |
11.6.3.4. Mexiletine |
11.6.3.5. Verapamil |
11.6.3.6. N-acetylprocainamide, NAPA |
11.6.3.7. Digitoxin |
11.6.3.8. Lidocaine |
11.6.3.9. Procainimide |
11.6.3.10. Quinidine |
11.7. Anticancer |
11.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.7.3. Market Opportunity Analysis |
11.7.3.1. 5-Fluorouracil |
11.7.3.2. Docetaxel |
11.7.3.3. Methotrexate |
11.7.3.4. Mylmatinib |
11.7.3.5. Paclitaxel |
11.7.3.6. Imatinib |
11.7.3.7. Busulfan |
11.8. Anticoagulants |
11.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.8.3. Market Opportunity Analysis |
11.8.3.1. Dabigatran |
11.8.3.2. Warfarin |
11.9. Antidepressants |
11.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.9.3. Market Opportunity Analysis |
11.9.3.1. Citalopram |
11.9.3.2. Fluoxetine |
11.9.3.3. Fluvoxamine |
11.9.3.4. Sertraline |
11.9.3.5. Venlafaxine |
11.9.3.6. Desmethylfluoxetine |
11.9.3.7. Trazodone |
11.9.3.8. Protriptyline |
11.9.3.9. Nortriptyline |
11.9.3.10. Imipramine |
11.9.3.11. Desipramine |
11.9.3.12. Doxepin |
11.9.3.13. Clomipramine |
11.9.3.14. Bupropion |
11.9.3.15. Amitriptyline |
11.9.3.16. Nortriptyline |
11.10. Antiepileptics |
11.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.10.3. Market Opportunity Analysis |
11.10.3.1. Ethosuximide |
11.10.3.2. Felbamate |
11.10.3.3. Gabapentin |
11.10.3.4. Lamotrigine |
11.10.3.5. Pregabaline |
11.10.3.6. Topiramate |
11.10.3.7. Zonisamide |
11.10.3.8. Carbamazepine |
11.10.3.9. Valproic Acid |
11.10.3.10. Lacosamide |
11.10.3.11. Levetiracetam |
11.10.3.12. Phenobarbital |
11.10.3.13. Phenytoin |
11.10.3.14. Rufinamide |
11.10.3.15. Tiagabine |
11.10.3.16. Vigabatrin |
11.10.3.17. Primidone |
11.11. Anti-HIV |
11.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.11.3. Market Opportunity Analysis |
11.11.3.1. Atazanavir |
11.11.3.2. Indinavir |
11.11.3.3. Lopinavir |
11.11.3.4. Nelfinavir |
11.11.3.5. Ritonavir |
11.11.3.6. Saquinavir |
11.11.3.7. Darunavir |
11.11.3.8. Fosamprenavir |
11.11.3.9. Tipranavir |
11.11.3.10. Efavirenz |
11.11.3.11. Etravirine |
11.11.3.12. Nevirapine |
11.11.3.13. Rilpivirine |
11.12. Antihypertensive |
11.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.12.3. Market Opportunity Analysis |
11.12.3.1. Propronolol |
11.13. Antipsychotics |
11.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.13.3. Market Opportunity Analysis |
11.13.3.1. Aripiprazole |
11.13.3.2. Clozapine |
11.13.3.3. Haloperidol |
11.13.3.4. Olanzapine |
11.13.3.5. Ziprasidone |
11.13.3.6. Chlorpromazine |
11.13.3.7. Lithium |
11.13.3.8. Lurasidone |
11.13.3.9. Paliperidone |
11.13.3.10. Perphenazine |
11.13.3.11. Quetiapine |
11.13.3.12. Risperidone |
11.13.3.13. Thiothixene |
11.14. Hormones |
11.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.14.3. Market Opportunity Analysis |
11.14.3.1. T3 |
11.14.3.2. T4 |
11.14.3.3. Corticosteroids |
11.14.3.4. TSH |
11.15. Immuno-Suppressants |
11.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.15.3. Market Opportunity Analysis |
11.15.3.1. Cyclosporin A |
11.15.3.2. Everolimus |
11.15.3.3. Mycophenolic acid |
11.15.3.4. Sirolimus |
11.15.3.5. Tacrolimus |
11.16. Antifungals |
11.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
11.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.16.3. Market Opportunity Analysis |
11.16.3.1. Fluconazole |
11.16.3.2. Itraconazole |
11.16.3.3. Voriconazole |
11.16.3.4. Posoconazole |
11.17. Immuno- Assay |
11.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.17.3. Market Opportunity Analysis |
11.18. Mass Spectrometry |
11.18.1. LC-MS/MS |
11.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.18.1.3. Market Opportunity Analysis |
11.18.2. GC-MS/MS |
11.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.18.2.3. Market Opportunity Analysis |
11.19. Others (Electrophoresis, Proteomics, etc.) |
11.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.19.3. Market Opportunity Analysis |
11.20. Latin America Therapeutic Drug Monitoring (TDM) Market By End User |
11.20.1. Hospital Laboratories |
11.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.20.1.3. Market Opportunity Analysis |
11.20.2. Private Laboratories |
11.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.20.2.3. Market Opportunity Analysis |
11.21. Latin America Therapeutic Drug Monitoring (TDM) Market By Country |
11.21.1. Brazil |
11.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.21.1.3. Market Opportunity Analysis |
11.21.2. Rest of LATAM |
11.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
11.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
11.21.2.3. Market Opportunity Analysis |
11.22. Latin America Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends |
12. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market Analysis, 2017 – 2021 and Forecast, 2018 – 2028 |
12.1. Antibiotics |
12.1.1. Antibiotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.1.3. Market Opportunity Analysis |
12.1.3.1. Chloramphenicol |
12.1.3.2. Linezolid |
12.1.3.3. Piperacillin |
12.1.3.4. Rifampicin |
12.1.3.5. Tazobactam |
12.1.3.6. Vancomycin |
12.1.3.7. Gentamicin |
12.1.3.8. Amikacin |
12.1.3.9. Tobramycin |
12.1.3.10. Teicoplanin |
12.1.3.11. Ceftazidime |
12.1.3.12. Meropenem |
12.1.3.13. Nafcillin |
12.1.3.14. Ticarcillin |
12.2. Addiction Therapeutics |
12.2.1. Addiction Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.2.3. Market Opportunity Analysis |
12.2.3.1. Buprenorphine |
12.2.3.2. Methadone |
12.2.3.3. Naltrexone |
12.2.3.4. Propoxyphene |
12.2.3.5. Tapentadol |
12.3. Alzheimer Disease |
12.3.1. Alzheimer Disease Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.3.3. Market Opportunity Analysis |
12.3.3.1. Donezepil |
12.3.3.2. Galantamine |
12.3.3.3. Memantine |
12.4. Analeptics |
12.4.1. Analeptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.4.3. Market Opportunity Analysis |
12.4.3.1. Caffeine |
12.4.3.2. Theophylline |
12.5. Analgesics |
12.5.1. Analgesics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.5.3. Market Opportunity Analysis |
12.5.3.1. Acetaminophen |
12.5.3.2. Ibuprofen |
12.5.3.3. Naproxen |
12.5.3.4. Salicylate |
12.5.3.5. Tramadol |
12.6. Antiarrhythmic |
12.6.1. Antiarrythmic Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.6.3. Market Opportunity Analysis |
12.6.3.1. Amiodarone |
12.6.3.2. Digoxin |
12.6.3.3. Flecainide |
12.6.3.4. Mexiletine |
12.6.3.5. Verapamil |
12.6.3.6. N-acetylprocainamide, NAPA |
12.6.3.7. Digitoxin |
12.6.3.8. Lidocaine |
12.6.3.9. Procainimide |
12.6.3.10. Quinidine |
12.7. Anticancer |
12.7.1. Anticancer Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.7.3. Market Opportunity Analysis |
12.7.3.1. 5-Fluorouracil |
12.7.3.2. Docetaxel |
12.7.3.3. Methotrexate |
12.7.3.4. Mylmatinib |
12.7.3.5. Paclitaxel |
12.7.3.6. Imatinib |
12.7.3.7. Busulfan |
12.8. Anticoagulants |
12.8.1. Anticoagulants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.8.3. Market Opportunity Analysis |
12.8.3.1. Dabigatran |
12.8.3.2. Warfarin |
12.9. Antidepressants |
12.9.1. Antidepressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.9.3. Market Opportunity Analysis |
12.9.3.1. Citalopram |
12.9.3.2. Fluoxetine |
12.9.3.3. Fluvoxamine |
12.9.3.4. Sertraline |
12.9.3.5. Venlafaxine |
12.9.3.6. Desmethylfluoxetine |
12.9.3.7. Trazodone |
12.9.3.8. Protriptyline |
12.9.3.9. Nortriptyline |
12.9.3.10. Imipramine |
12.9.3.11. Desipramine |
12.9.3.12. Doxepin |
12.9.3.13. Clomipramine |
12.9.3.14. Bupropion |
12.9.3.15. Amitriptyline |
12.9.3.16. Nortriptyline |
12.10. Antiepileptics |
12.10.1. Antiepileptics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.10.3. Market Opportunity Analysis |
12.10.3.1. Ethosuximide |
12.10.3.2. Felbamate |
12.10.3.3. Gabapentin |
12.10.3.4. Lamotrigine |
12.10.3.5. Pregabaline |
12.10.3.6. Topiramate |
12.10.3.7. Zonisamide |
12.10.3.8. Carbamazepine |
12.10.3.9. Valproic Acid |
12.10.3.10. Lacosamide |
12.10.3.11. Levetiracetam |
12.10.3.12. Phenobarbital |
12.10.3.13. Phenytoin |
12.10.3.14. Rufinamide |
12.10.3.15. Tiagabine |
12.10.3.16. Vigabatrin |
12.10.3.17. Primidone |
12.11. Anti-HIV |
12.11.1. Anti-HIV Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.11.3. Market Opportunity Analysis |
12.11.3.1. Atazanavir |
12.11.3.2. Indinavir |
12.11.3.3. Lopinavir |
12.11.3.4. Nelfinavir |
12.11.3.5. Ritonavir |
12.11.3.6. Saquinavir |
12.11.3.7. Darunavir |
12.11.3.8. Fosamprenavir |
12.11.3.9. Tipranavir |
12.11.3.10. Efavirenz |
12.11.3.11. Etravirine |
12.11.3.12. Nevirapine |
12.11.3.13. Rilpivirine |
12.12. Antihypertensive |
12.12.1. Antihypertensive Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.12.3. Market Opportunity Analysis |
12.12.3.1. Propronolol |
12.13. Antipsychotics |
12.13.1. Antipsychotics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.13.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.13.3. Market Opportunity Analysis |
12.13.3.1. Aripiprazole |
12.13.3.2. Clozapine |
12.13.3.3. Haloperidol |
12.13.3.4. Olanzapine |
12.13.3.5. Ziprasidone |
12.13.3.6. Chlorpromazine |
12.13.3.7. Lithium |
12.13.3.8. Lurasidone |
12.13.3.9. Paliperidone |
12.13.3.10. Perphenazine |
12.13.3.11. Quetiapine |
12.13.3.12. Risperidone |
12.13.3.13. Thiothixene |
12.14. Hormones |
12.14.1. Hormones Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.14.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.14.3. Market Opportunity Analysis |
12.14.3.1. T3 |
12.14.3.2. T4 |
12.14.3.3. Corticosteroids |
12.14.3.4. TSH |
12.15. Immuno-Suppressants |
12.15.1. Immuno-Suppressants Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.15.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.15.3. Market Opportunity Analysis |
12.15.3.1. Cyclosporin A |
12.15.3.2. Everolimus |
12.15.3.3. Mycophenolic acid |
12.15.3.4. Sirolimus |
12.15.3.5. Tacrolimus |
12.16. Antifungals |
12.16.1. Antifungals Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue (USD Million), Test Volume (Millions), and Patients) |
12.16.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.16.3. Market Opportunity Analysis |
12.16.3.1. Fluconazole |
12.16.3.2. Itraconazole |
12.16.3.3. Voriconazole |
12.16.3.4. Posoconazole |
12.17. Immuno- Assay |
12.17.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.17.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.17.3. Market Opportunity Analysis |
12.18. Mass Spectrometry |
12.18.1. LC-MS/MS |
12.18.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.18.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.18.1.3. Market Opportunity Analysis |
12.18.2. GC-MS/MS |
12.18.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.18.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.18.2.3. Market Opportunity Analysis |
12.19. Others (Electrophoresis, Proteomics, etc.) |
12.19.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.19.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.19.3. Market Opportunity Analysis |
12.20. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market By End User |
12.20.1. Hospital Laboratories |
12.20.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.20.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.20.1.3. Market Opportunity Analysis |
12.20.2. Private Laboratories |
12.20.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.20.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.20.2.3. Market Opportunity Analysis |
12.21. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market By Country |
12.21.1. Japan |
12.21.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.21.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.21.1.3. Market Opportunity Analysis |
12.21.2. China |
12.21.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.21.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.21.2.3. Market Opportunity Analysis |
12.21.3. Australia |
12.21.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.21.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.21.3.3. Market Opportunity Analysis |
12.21.4. S.Korea |
12.21.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 ((Revenue, USD Millions) (Volume Millions)) |
12.21.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
12.21.4.3. Market Opportunity Analysis |
12.22. Asia-Pacific Therapeutic Drug Monitoring (TDM) Market Dynamics – Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Analyte & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. Beckman Coulter Inc. (U.S.) |
13.2.2. Hoffmann-La Roche (U.S.) |
13.2.3. Bio-Rad Laboratories Inc. (U.S.) |
13.2.4. Thermo Fisher Scientific (U.S.) |
13.2.5. Siemens Healthineers (Siemens AG (Germany) |
13.2.6. Abbott (Alere Inc.) (U.S.) |
13.2.7. Diagnostics GmbH (Germany) |
13.2.8. Grifols (Spain) |
13.2.9. BÜHLMANN Laboratories AG (Germany) |
13.2.10. bioMérieux (U.S.) |
13.2.11. Merck Millipore (E. Merck KG) (Germany) |
13.2.12. DiaSorin (Italy) |
13.2.13. Myriad Genetics (U.S.) |
13.2.14. Miraca Life Sciences (Miraca Holdings Inc.) (Japan) |
13.2.15. Roche Diagnostics (Switzerland) |
13.2.16. Chromsystems (Germany) |
13.2.17. Phamatech, Inc (U.S.) |
13.2.18. Randox Laboratories Ltd. (U.K.) |
13.2.19. SEKISUI MEDICAL CO., LTD. (Japan) |
14. Research Methodology |
15. Key Assumptions and Acronyms |